Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

Therapeutics that target ERBB2, such as lapatinib, often provide initial clinical benefit, but resistance frequently develops. Adaptive responses leading to lapatinib resistance involve reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and transcriptional upregulation and act...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Timothy J. Stuhlmiller, Samantha M. Miller, Jon S. Zawistowski, Kazuhiro Nakamura, Adriana S. Beltran, James S. Duncan, Steven P. Angus, Kyla A.L. Collins, Deborah A. Granger, Rachel A. Reuther, Lee M. Graves, Shawn M. Gomez, Pei-Fen Kuan, Joel S. Parker, Xin Chen, Noah Sciaky, Lisa A. Carey, H. Shelton Earp, Jian Jin, Gary L. Johnson
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2015-04-01
Schriftenreihe:	Cell Reports
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S221112471500306X
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!